Announcement on Progress in Repurchasing Shares
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Chengdu Easton Biopharmaceuticals Co., Ltd. has announced progress in its share repurchase plan. The repurchase is aimed at maintaining company value and protecting shareholder interests.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/chengdu-easton-biopharmaceuticals-co-ltdannouncement-on-progress-in-repurchasing-shares
Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix
Earlier from Chengdu Easton Biopharmaceuticals
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for HP-002 Tablets and Completion of First Subject Enrollment and Dosing
- Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement
- Announcement on the Voluntary Disclosure of Obtaining Drug Registration Certificate for Remimazolam Besylate for Injection
- Announcement on Abnormal Fluctuations in Stock Trading
Later from Chengdu Easton Biopharmaceuticals
- Announcement on Implementation Results of Share Repurchase
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on Resolutions of the 16th Meeting of the 4th Board of Directors
- Announcement on Voluntary Disclosure of Progress of Phase I Clinical Trials for EP-0226 Tablets
Follow Chengdu Easton Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Easton Biopharmaceuticals